Is anti-PD-1 immunotherapy a means for post-irradiation tumor clearance in head and neck cancer?

Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, Lonati V, Sarti E, Barni S. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol. 2014;50:1041–8. https://doi.org/10.1016/j.oraloncology.2014.08.005.

CAS  Article  PubMed  Google Scholar 

Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator’s choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head Neck. 2020;42:2852–62. https://doi.org/10.1002/hed.26331.

Article  PubMed  PubMed Central  Google Scholar 

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.

CAS  Article  PubMed  Google Scholar 

Yu Y, Zakeri K, Lee N. Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy? Oncotarget. 2021;12:2223–6. https://doi.org/10.18632/oncotarget.27987.

Article  PubMed  PubMed Central  Google Scholar 

Koukourakis IM, Zygogianni A, Kouloulias V, Kyrgias G, Panteliadou M, Nanos C, Abatzoglou I, Koukourakis MI. Is Locally Advanced head-neck cancer one more candidate for accelerated hypofractionation? Anticancer Res. 2021;41:467–75. https://doi.org/10.21873/anticanres.14797.

CAS  Article  PubMed  Google Scholar 

Mulkey F, Theoret MR, Keegan P, Pazdur R, Sridhara R. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. J Immunother Cancer. 2020;8:e000146. https://doi.org/10.1136/jitc-2019-000146.

Article  PubMed  PubMed Central  Google Scholar 

Milanovic M, Fan DNY, Belenki D, Däbritz JHM, Zhao Z, Yu Y, Dörr JR, Dimitrova L, Lenze D, Monteiro Barbosa IA, Mendoza-Parra MA, Kanashova T, Metzner M, Pardon K, Reimann M, Trumpp A, Dörken B, Zuber J, Gronemeyer H, Hummel M, Dittmar G, Lee S, Schmitt CA. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96–100. https://doi.org/10.1038/nature25167.

CAS  Article  PubMed  Google Scholar 

Koukourakis MI, Giatromanolaki A. Tumor microenvironment, immune response and post-radiotherapy tumor clearance. Clin Transl Oncol. 2020;22:2196–205. https://doi.org/10.1007/s12094-020-02378-8.

CAS  Article  PubMed  Google Scholar 

Hanai N, Shimizu Y, Kariya S, et al. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol. 2012;26:494–506. https://doi.org/10.1007/s10147-020-01829-0.

CAS  Article  Google Scholar 

Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994–3006. https://doi.org/10.1002/1878-0261.12851.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25:11–7. https://doi.org/10.1016/j.semradonc.2014.07.005.

Article  PubMed  Google Scholar 

Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67:65–85. https://doi.org/10.3322/caac.21358.

Article  PubMed  Google Scholar 

Cohen EE, Ferris RL, Psyrri A, Haddad R, Tahara M, Bourhis J, Harrington KJ, Chang PM-H, Lin JC, Razaq M, Teixeira MM, Lovey J, Chamois J, Rueda Dominguez A, Hu C, Dvorkin M, De Beukelaer S, Pavlov D, Thurm H, Lee N. 910O-Primary results of the phase III JAVELIN head & neck 100 trial: avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally 1280 advanced squamous cell carcinoma of the head and neck (LA SCCHN). Ann Oncol. 2020;suppl4(31):S599–628. https://doi.org/10.1016/annonc/annonc277.

Article  Google Scholar 

Bourhis J, Tao SY, Martin L, Alfonsi M, Prevost JB, Rives M, Lafond C, Tourani JM, Biau J, Geoffrois L, Coutte A, Liem X, Drouet F, Pechery A, Guigay J, Wanneveich M, Auperin A, Sun X. LBA38 Pembrolizumab versus cetuximab, concomitant with 1283 radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): results of the GORTEC 2015–01 ‘PembroRad’ randomized trial. Ann Oncol. 2020;31:S1168. https://doi.org/10.1016/j.annonc.2020.08.2268.

Article  Google Scholar 

du Bois H, Heim TA, Lund AW. Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci Immunol. 2021;6:eabg 3551. https://doi.org/10.1126/sciimmunol.abg3551.

CAS  Article  Google Scholar 

Formenti SC. Optimizing dose per fraction: a new chapter in the story of the abscopal Effect? Int J Radiat Oncol Biol Phys. 2017;99:677–9. https://doi.org/10.1016/j.ijrobp.2017.07.028.

Article  PubMed  Google Scholar 

Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Özgüroğlu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol. 2021;16:860–7. https://doi.org/10.1016/j.jtho.2020.12.015.

CAS  Article  PubMed  Google Scholar 

Ding X, Liu YP, Hua YJ, Zou X, Wang ZQ, Xie YL, Chen MY. Clinical advances in nasopharyngeal carcinoma surgery and a video demonstration. Vis Cancer Med. 2021. https://doi.org/10.1051/vcm/2021001.

Article  Google Scholar 

Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G Jr, Gunuganti V, Li A, Aanur N, Spigel DR. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkmate 153. J Clin Oncol. 2020;20(38):3863–73. https://doi.org/10.1200/JCO.20.00131.

Article  Google Scholar 

Shukla N, Hanna N, Durm G. Optimal duration of maintenance checkpoint inhibitor therapy in patients with advanced NSCLC. JCO Oncol Pract. 2021;17:472–4. https://doi.org/10.1200/OP.21.00059 (Epub 2021 May 3).

Article  PubMed  Google Scholar 

Eun Y, Kim IY, Sun JM, Lee J, Cha HS, Koh EM, Kim H, Lee J. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019;9:14039. https://doi.org/10.1038/s41598-019-50574-6.

CAS  Article  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif